Shingles vaccine has unexpected effect on heart health
Beyond protecting against the viral infection and resulting painful rash, the shot has also been linked to a reduced risk of dementia, as Fox News Digital previously reported.
And now, a new study has found that the vaccine could lower the risk of heart disease for up to eight years.
In the long-running study, researchers analyzed up to 12 years of data for more than 1.2 million people aged 50 or older in South Korea, focusing on shingles vaccination rates and 18 different types of cardiovascular disease.
They found that those who received the shingles vaccine had a 23% lower risk of heart issues, including stroke, heart failure and coronary artery disease.
The benefits were greater for people under 60 years old, likely because they have a better immune response, according to the researchers.
The vaccine's heart health benefits were also more prominent among men and those who have unhealthy behaviors, such as being sedentary, drinking alcohol and smoking.
The findings were published in the European Heart Journal on Tuesday.
The primary symptom of shingles is a painful rash that can lead to serious complications, particularly for older adults and those with weak immune systems, according to lead author Professor Dong Keon Yon from the Kyung Hee University College of Medicine, Seoul, South Korea.
Without vaccination, about 30% of people may develop shingles in their lifetime, Yon noted.
"In addition to the rash, shingles has been linked to a higher risk of heart problems, so we wanted to find out if getting vaccinated could lower this risk," he said in a press release.
"Our study suggests that the shingles vaccine may help lower the risk of heart disease, even in people without known risk factors."
"Our study suggests that the shingles vaccine may help lower the risk of heart disease, even in people without known risk factors. This means that vaccination could offer health benefits beyond preventing shingles."
The researchers shared several possible reasons for the vaccine's protective effect on heart health.
"A shingles infection can cause blood vessel damage, inflammation and clot formation that can lead to heart disease," Yon said. "By preventing shingles, vaccination may lower these risks."
Dr. Jasdeep Dalawari, a Virginia-based interventional cardiologist and regional chief medical officer at VitalSolution, an Ingenovis Health company, was not involved in the study but offered his comments on the findings.
"This result is notable but requires careful interpretation, especially for the U.S. population," he told Fox News Digital.
"The study used a live vaccine, whereas the U.S. uses Shingrix, a recombinant (non-live) vaccine," Dalawari noted. "It's important to note that Shingrix is over 90% effective against shingles, compared to the live vaccine's 51%."
The live zoster vaccine contains a weakened form of the varicella zoster virus that causes shingles.
The cardiologist also pointed out that the observational study shows correlation, not causation, and that further research is needed.
"The study included 1.2 million individuals aged 50+, all from one ethnicity," he said. "Expanding the participant pool to include diverse ethnicities would be beneficial in our multi-ethnic society."
Although the study did consider other health conditions, lifestyle factors and socioeconomic status, the researchers agreed that it had some limitations.
"As this study is based on an Asian cohort, the results may not apply to all populations," Yon noted. "While we conducted rigorous analysis, this study does not establish a direct causal relationship, so potential bias from other underlying factors should be considered."
The team plans to conduct further research into the heart health benefits of the non-live, recombinant vaccine, which contains a protein from the virus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 minutes ago
- Medscape
Think of Exercise as a Vaccine for Your Body
This transcript has been edited for clarity. Let's talk today about how exercise can be viewed as a type of vaccine. With a traditional vaccine, there is a controlled exposure to something harmful, which is typically a viral particle. That exposure, though, allows the immune system to be prepared to deal with that virus if it sees it again later on. Exercise also has the appearance of harm on the surface. It doesn't always feel good in the moment. The whole body is working harder to meet the demands of the exercise. As a result of that extra stress during the exercise activity, the body is then better prepared to deal with stress that can occur from disease processes later on. As a result of the aging process,organ systems are going to decline a little bit in function, and exercise is the best way to combat those declines. Let's think about something like pneumonia, where somebody might have a fever; they're going to be breathing heavy, and their heart's going to be working harder. For someone who's been exercising on a regular basis, their organ systems are better prepared to meet the higher demands associated with a disease process such as pneumonia. In contrast, for someone who has not been exercising frequently, their organ systems have declined in function, and then as a result, they're more likely to be overwhelmed during the disease process. Someone might need medications to support their blood pressure during a pneumonia situation. Someone else might need a mechanical ventilator. In this way, you could view exercise as training for the worst day of your life from a medical perspective. You want to make sure your organs are equipped to deal with stress when it's occurring in an uncontrolled environment, like from an infection such as pneumonia. Vaccines may be a controversial topic for some, but I think exercise is one type of vaccine whose benefits we can all agree upon.
CBS News
40 minutes ago
- CBS News
Mayo Clinic refused employee's COVID-19 vaccine exemption request, lawsuit says
A lawsuit filed by the U.S. Equal Employment Opportunity Commission on Thursday alleges the Mayo Clinic violated federal law when it refused a security guard's request to be exempt from getting the COVID-19 vaccine due to his religious beliefs. Mayo implemented a mandatory COVID-19 vaccination policy around Oct. 13, 2021, which required all of its employees to receive the vaccine by Dec. 3, 2021, unless they received a medical or religious exemption, according to the court document. Anyone who didn't follow the policy would be terminated. On Nov. 1, 2021, the security guard, who was not named in the lawsuit, submitted an accommodation form to the clinic requesting that he be exempt from the policy, stating "his religious observance or practice conflicted with the COVID-19 vaccine," the complaint said. According to the lawsuit, the form stated he is a member of an Assemblies of God Church, which believes the vaccine contained ingredients that "were inconsistent with his religious belief," and he could not "put those ingredients in his body." The employee also believed that if he were to die from the vaccine, it would be considered suicide and undermine God's faith. The security guard said he would be willing to wear a mask and take COVID-19 tests if he were granted an exemption to the policy. On Nov. 21, 2021, Mayo denied the request, stating the employee didn't meet the criteria for a religious exemption, the lawsuit said. The security guard submitted a reconsideration request the next day. Mayo denied the reconsideration request on Dec. 1 and said he must get the vaccine or else he would be fired. The clinic issued a final written warning to the security guard on Dec. 3, saying he would be terminated if he did not receive the vaccine by January 2022. The EEOC alleges Mayo violated Title VII of the Civil Rights Act, which prohibits companies from discriminating against employees based on religion. The federal agency is seeking monetary damages, though it's unclear how much. According to the lawsuit, the EEOC is also asking Mayo to implement policies and programs that "provide equal employment opportunities for religious persons." A spokesperson for Mayo Clinic said the company would not comment "due to pending litigation."
Yahoo
4 hours ago
- Yahoo
Why Moderna (MRNA) Stock Is Trading Lower Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper end of its 2025 revenue forecast, citing a delay in vaccine shipments. The company pointed to a delay in vaccine deliveries to the United Kingdom, which it pushed into the first quarter of 2026. This news overshadowed second-quarter results that beat Wall Street expectations. For the quarter, Moderna's revenue dropped about 41% from the previous year to $142 million, driven by lower sales of its COVID-19 vaccine. Despite the revenue decline, the company successfully narrowed its net loss as its cost-cutting measures took effect. Adding to the pressure, Moderna also announced plans to reduce its workforce by 10% and confirmed a delay in the U.S. approval for its combined COVID-flu vaccine until 2026. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Moderna? Access our full analysis report here, it's free. What Is The Market Telling Us Moderna's shares are extremely volatile and have had 53 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 4.9% on the news that industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector. The core of the issue stems from an 'unprecedented medical cost trend environment,' particularly within the Medicare Advantage market, which are privately run versions of the federal health insurance program. UnitedHealth, the largest provider in this space, now expects these costs to rise by 7.5% in 2025, a significant jump from its earlier 5% projection, with the potential to accelerate to almost 10% in 2026. In response, the insurer announced it will drop plans covering over 600,000 people. The company's lowered earnings forecast has raised investor concerns that these surging costs and utilization rates are an industry-wide problem, impacting the profitability of other carriers as well. Moderna is down 34.6% since the beginning of the year, and at $27.47 per share, it is trading 70.8% below its 52-week high of $94.17 from July 2024. Investors who bought $1,000 worth of Moderna's shares 5 years ago would now be looking at an investment worth $352.27. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. 登入存取你的投資組合
